Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

262
The pathophysiology of pneumonia involves the following steps:
262
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

233
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
233
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

228
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
228
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

325
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
325
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

242
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
242
Pneumonia IV: Management01:28

Pneumonia IV: Management

324
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
324

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical evaluation of the diagnostic performances and treatment monitoring of the new PATHFAST TB LAM Ag assay in sputum specimens of patients with tuberculosis or with nontuberculous mycobacteria pulmonary disease.

Journal of clinical microbiology·2025
Same author

An insight into the characterization of L2 Beijing multi-drug resistant tuberculosis: Description of resistance-associated-variants and discovery of Modern 7 L2 sublineage.

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases·2025
Same author

Standardised protocol for the detection and quantification of nontuberculous mycobacteria (NTM) in tap water and its application in investigating the source of NTM clinical infections.

International journal of hygiene and environmental health·2025
Same author

D-PRISM: a global survey-based study to assess diagnostic and treatment approaches in pneumonia managed in intensive care.

Critical care (London, England)·2024
Same author

Amoeba plate test with <i>Acanthamoeba castellanii</i> as an innovative tool for <i>Nocardia</i> recovery from sputum samples: a proof-of-concept study.

Microbiology spectrum·2024
Same author

Developing a sustainable team in critical care: focus on gender-based diversity.

Anaesthesia, critical care & pain medicine·2024

Related Experiment Video

Updated: Jun 29, 2025

Use of Galleria mellonella as a Model Organism to Study Legionella pneumophila Infection
12:30

Use of Galleria mellonella as a Model Organism to Study Legionella pneumophila Infection

Published on: November 22, 2013

40.4K

Severe Legionnaires' disease.

Jordi Rello1,2, Camille Allam3,4, Alfonsina Ruiz-Spinelli5

  • 1Global Health ECore, Vall d'Hebron Institut of Research (VHIR), Barcelona, Spain.

Annals of Intensive Care
|April 2, 2024
PubMed
Summary

Legionnaires

Keywords:
Acute respiratory distress syndromeBiomarkersImmunocompromised patientsLegionellosisLegionnaires’ diseaseLevofloxacinMacrolidesSevere community-acquired pneumonia

More Related Videos

Legionella pneumophila Outer Membrane Vesicles: Isolation and Analysis of Their Pro-inflammatory Potential on Macrophages
08:34

Legionella pneumophila Outer Membrane Vesicles: Isolation and Analysis of Their Pro-inflammatory Potential on Macrophages

Published on: February 22, 2017

11.2K
Tractable Mammalian Cell Infections with Protozoan-primed Bacteria
13:54

Tractable Mammalian Cell Infections with Protozoan-primed Bacteria

Published on: April 2, 2013

10.5K

Related Experiment Videos

Last Updated: Jun 29, 2025

Use of Galleria mellonella as a Model Organism to Study Legionella pneumophila Infection
12:30

Use of Galleria mellonella as a Model Organism to Study Legionella pneumophila Infection

Published on: November 22, 2013

40.4K
Legionella pneumophila Outer Membrane Vesicles: Isolation and Analysis of Their Pro-inflammatory Potential on Macrophages
08:34

Legionella pneumophila Outer Membrane Vesicles: Isolation and Analysis of Their Pro-inflammatory Potential on Macrophages

Published on: February 22, 2017

11.2K
Tractable Mammalian Cell Infections with Protozoan-primed Bacteria
13:54

Tractable Mammalian Cell Infections with Protozoan-primed Bacteria

Published on: April 2, 2013

10.5K

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Critical Care Medicine

Background:

  • Legionnaires' disease (LD) is an underdiagnosed cause of community-acquired pneumonia (CAP).
  • LD requires intensive care unit (ICU) admission in nearly one-third of cases, with mortality rates ranging from 4% to 40%.
  • Recent diagnostic and therapeutic advances have improved the management of severe LD.

Purpose of the Study:

  • To review recent advances in Legionnaires' disease research.
  • To provide an update on the diagnosis, pathogenesis, and management of severe LD.

Main Methods:

  • Review of recent literature on Legionnaires' disease.
  • Analysis of diagnostic methods including urine antigen testing (UAT) and molecular testing.
  • Discussion of current and emerging therapeutic strategies.

Main Results:

  • Legionnaires' disease incidence is increasing globally, particularly in immunocompromised individuals.
  • Severe LD is associated with high pulmonary Legionella DNA loads and immune response impairments.
  • Improved diagnostic tools like UAT and molecular methods enhance detection across all Legionella pneumophila serogroups.

Conclusions:

  • Mortality in severe LD is influenced by ICU admission, immune status, and infection source.
  • Host immune responses, including hyperinflammation or immunoparalysis, correlate with disease severity.
  • Further research into severity biomarkers and host-directed therapies is warranted given rising LD incidence.